[go: up one dir, main page]

AR011860A1 - Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas - Google Patents

Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas

Info

Publication number
AR011860A1
AR011860A1 ARP980100810A ARP980100810A AR011860A1 AR 011860 A1 AR011860 A1 AR 011860A1 AR P980100810 A ARP980100810 A AR P980100810A AR P980100810 A ARP980100810 A AR P980100810A AR 011860 A1 AR011860 A1 AR 011860A1
Authority
AR
Argentina
Prior art keywords
preparation
neurodegenerative diseases
dementia
application
procedure
Prior art date
Application number
ARP980100810A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR011860A1 publication Critical patent/AR011860A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Preparado de combinacion para la aplicacion en la demencia, que contiene al menos: 1) un compuesto que presenta un efecto inhibidor de laacetilcolinesterasa o muestra un efecto muscarinogeno; 2) un compuesto que aumenta el nivel de adenosinaextracelular endogeno; 3) un soportefarmacéutico, con un aumento supraaditivo del efecto muscarínico en el caso de enfermedades neurodegenerativas, para la aplicacion simultánea, separadao escalonada en el tiempo. Además la invencion describe unprocedimiento para la produccion del preparado y el empleo del mismo para la preparacion de unmedicamento util para el tratamiento de enfermedades neurodegenerativas, en particular la demencia senil.
ARP980100810A 1997-02-26 1998-02-24 Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas AR011860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (de) 1997-02-26 1997-02-26 Kombinationspräparat zur Anwendung bei Demenz

Publications (1)

Publication Number Publication Date
AR011860A1 true AR011860A1 (es) 2000-09-13

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100810A AR011860A1 (es) 1997-02-26 1998-02-24 Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas

Country Status (30)

Country Link
US (1) US6037347A (es)
EP (1) EP0867192B1 (es)
JP (1) JP4374440B2 (es)
KR (1) KR100517186B1 (es)
CN (1) CN100363005C (es)
AR (1) AR011860A1 (es)
AT (1) ATE295738T1 (es)
AU (1) AU749278C (es)
BR (1) BR9800766A (es)
CA (1) CA2230350C (es)
CZ (1) CZ298367B6 (es)
DE (2) DE19707655A1 (es)
DK (1) DK0867192T3 (es)
EE (1) EE03387B1 (es)
ES (1) ES2242243T3 (es)
HR (1) HRP980097B1 (es)
HU (1) HUP9800396A3 (es)
ID (1) ID19941A (es)
IL (1) IL123453A (es)
MY (1) MY120530A (es)
NO (1) NO327200B1 (es)
NZ (1) NZ329839A (es)
PL (1) PL191576B1 (es)
PT (1) PT867192E (es)
RU (1) RU2194508C2 (es)
SI (1) SI0867192T1 (es)
SK (1) SK284925B6 (es)
TR (1) TR199800302A2 (es)
TW (1) TW590772B (es)
ZA (1) ZA981561B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286725T1 (de) * 1998-10-01 2005-01-15 Novartis Pharma Gmbh Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP5597343B2 (ja) * 2005-04-28 2014-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有する組成物
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
EP0179383B1 (en) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
MX13270A (es) * 1987-10-05 1993-06-01 Pfizer Procedimiento para la preparacion de derivados de 4-aminopiridina
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
RU2039058C1 (ru) * 1988-03-30 1995-07-09 Пфайзер Инк. Производные 4-аминопиридина
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
AU643235B2 (en) * 1989-09-15 1993-11-11 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
RU2024509C1 (ru) * 1991-05-07 1994-12-15 Всероссийский научный центр по безопасности биологически активных веществ Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
KR100517186B1 (ko) 2005-12-05
HU9800396D0 (en) 1998-04-28
PL325074A1 (en) 1998-08-31
DK0867192T3 (da) 2005-09-05
MY120530A (en) 2005-11-30
BR9800766A (pt) 1999-12-07
ES2242243T3 (es) 2005-11-01
ATE295738T1 (de) 2005-06-15
EP0867192A3 (de) 2000-12-06
JP4374440B2 (ja) 2009-12-02
CN100363005C (zh) 2008-01-23
IL123453A (en) 2004-06-20
NZ329839A (en) 2000-05-26
JPH10236979A (ja) 1998-09-08
DE59812801D1 (de) 2005-06-23
TW590772B (en) 2004-06-11
SK284925B6 (sk) 2006-02-02
NO980786L (no) 1998-08-27
PL191576B1 (pl) 2006-06-30
CN1192904A (zh) 1998-09-16
CZ54098A3 (cs) 1998-09-16
SK24098A3 (en) 1998-09-09
HUP9800396A1 (hu) 1999-07-28
EP0867192B1 (de) 2005-05-18
IL123453A0 (en) 1998-09-24
KR19980071717A (ko) 1998-10-26
PT867192E (pt) 2005-08-31
AU5627398A (en) 1998-09-03
SI0867192T1 (en) 2005-10-31
AU749278B2 (en) 2002-06-20
DE19707655A1 (de) 1998-08-27
MX9801515A (es) 1998-08-30
CA2230350C (en) 2007-07-24
EE03387B1 (et) 2001-04-16
TR199800302A3 (tr) 1998-09-21
ZA981561B (en) 1998-08-26
EE9800075A (et) 1998-10-15
TR199800302A2 (xx) 1998-09-21
HUP9800396A3 (en) 2001-05-28
HRP980097A2 (en) 1998-12-31
NO327200B1 (no) 2009-05-11
AU749278C (en) 2003-07-31
US6037347A (en) 2000-03-14
ID19941A (id) 1998-08-27
CZ298367B6 (cs) 2007-09-12
NO980786D0 (no) 1998-02-25
EP0867192A2 (de) 1998-09-30
CA2230350A1 (en) 1998-08-26
RU2194508C2 (ru) 2002-12-20
HRP980097B1 (en) 2006-09-30

Similar Documents

Publication Publication Date Title
CA2359510A1 (en) .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR011860A1 (es) Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ES2189824T3 (es) Antagonistas no peptidicos del receptor de taquiquininas.
BR0213355A (pt) composições farmacêuticas
MXPA02007915A (es) Mediador de lipido activado por aspirina.
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
TW268937B (es)
MX9207008A (es) Medicamentos para el tratamiento de condiciones inflamatorias o para la analgesia.
BR0311347A (pt) Alcanóis bis-aromáticos
ECSP003707A (es) Diazepanes
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
PT1060175E (pt) Inibidores de triptase
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
SE9802937D0 (sv) Novel compounds
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
NO20021625L (no) Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog
MX9202507A (es) Composicion farmaceutica para el tratamiento de esofagitis de reflujo.
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.

Legal Events

Date Code Title Description
FC Refusal